Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956113889> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2956113889 abstract "e18524 Background: Traditionally, patients eligible for induction chemotherapy for AML are treated with the “7+3” regimen, standard doses of infusional cytarabine and an anthracycline, with historical CR rates of 50-60%. We present a retrospective analysis of an alternate induction regimen. Based on timed sequential therapy, it consists of a 2-day treatment with high dose cytarabine, which improves remission rates when used in induction, and dose intensified anthracycline therapy, which improves outcomes while maintaining an acceptable safety profile. Methods: 200 patients were treated from 2010-2015. Patients received 2 doses of cytarabine 2 gm/m 2 (1.5 gm/m 2 age > 70 years) IVPB over 3 hours, 12 hours apart followed by 1 dose of mitoxantrone 30 mg/m 2 IVPB over 1 hour on days 1 and 5. Cytogenetics and adverse events data were collected. IWG remission criteria were used to determine remission status. Results: Median age 57.6 years (range 23-79); 105 (53%) age > 60. 119 male; 81 female. Risk stratification: 12 favorable; 108 intermediate; 80 unfavorable . Overall CR rate (CRR: CR+CRi+CRp) for all patients was 68.5%. CR rates based on risk karyotypes: favorable 100%, intermediate 76.8%, unfavorable 52.5%. Most common G3-4 adverse events: anemia (60% G3, 40% G4), neutropenia (1% G3, 99% G4), thrombocytopenia (0.5% G1, 99.5% G4). 196 patients (98%) had neutropenic fever; 134 (67%) documented infections (100 with G3/4), 62 (31%) neutropenic fever with no source. 52 (26%) experienced bleeding (15 G1, 31 G2, 4 G3, 1 G4, 1 G5). G3/4 renal or hepatic toxicity was rare. No cerebellar toxicity occurred during induction. 30 day mortality 0.5%; 60 day mortality 3%. 62 (31%) patients are still alive; 122 died, 16 lost to follow-up. Conclusions: This two-day induction regimen is an effective treatment for AML with an acceptable safety profile including patients age >60. There is a high response rate, particularly for favorable and intermediate risk karyotypes, with a low rate of early mortality. The high response rates and tolerability with this regimen provides a platform for further clinical trials to enhance outcome by combining with novel targeted therapies for AML." @default.
- W2956113889 created "2019-07-12" @default.
- W2956113889 creator A5017312893 @default.
- W2956113889 creator A5024235943 @default.
- W2956113889 creator A5025499306 @default.
- W2956113889 creator A5038282364 @default.
- W2956113889 creator A5056684603 @default.
- W2956113889 creator A5058700214 @default.
- W2956113889 creator A5069120119 @default.
- W2956113889 date "2019-05-20" @default.
- W2956113889 modified "2023-09-27" @default.
- W2956113889 title "Timed sequential therapy with high-dose cytarabine and mitoxantrone as an induction regimen for acute myeloid leukemia: An update on adverse events." @default.
- W2956113889 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e18524" @default.
- W2956113889 hasPublicationYear "2019" @default.
- W2956113889 type Work @default.
- W2956113889 sameAs 2956113889 @default.
- W2956113889 citedByCount "0" @default.
- W2956113889 crossrefType "journal-article" @default.
- W2956113889 hasAuthorship W2956113889A5017312893 @default.
- W2956113889 hasAuthorship W2956113889A5024235943 @default.
- W2956113889 hasAuthorship W2956113889A5025499306 @default.
- W2956113889 hasAuthorship W2956113889A5038282364 @default.
- W2956113889 hasAuthorship W2956113889A5056684603 @default.
- W2956113889 hasAuthorship W2956113889A5058700214 @default.
- W2956113889 hasAuthorship W2956113889A5069120119 @default.
- W2956113889 hasConcept C126322002 @default.
- W2956113889 hasConcept C143998085 @default.
- W2956113889 hasConcept C197934379 @default.
- W2956113889 hasConcept C2776694085 @default.
- W2956113889 hasConcept C2778041864 @default.
- W2956113889 hasConcept C2778461978 @default.
- W2956113889 hasConcept C2778729363 @default.
- W2956113889 hasConcept C2780923524 @default.
- W2956113889 hasConcept C2781413609 @default.
- W2956113889 hasConcept C2991767035 @default.
- W2956113889 hasConcept C71924100 @default.
- W2956113889 hasConcept C98274493 @default.
- W2956113889 hasConceptScore W2956113889C126322002 @default.
- W2956113889 hasConceptScore W2956113889C143998085 @default.
- W2956113889 hasConceptScore W2956113889C197934379 @default.
- W2956113889 hasConceptScore W2956113889C2776694085 @default.
- W2956113889 hasConceptScore W2956113889C2778041864 @default.
- W2956113889 hasConceptScore W2956113889C2778461978 @default.
- W2956113889 hasConceptScore W2956113889C2778729363 @default.
- W2956113889 hasConceptScore W2956113889C2780923524 @default.
- W2956113889 hasConceptScore W2956113889C2781413609 @default.
- W2956113889 hasConceptScore W2956113889C2991767035 @default.
- W2956113889 hasConceptScore W2956113889C71924100 @default.
- W2956113889 hasConceptScore W2956113889C98274493 @default.
- W2956113889 hasLocation W29561138891 @default.
- W2956113889 hasOpenAccess W2956113889 @default.
- W2956113889 hasPrimaryLocation W29561138891 @default.
- W2956113889 hasRelatedWork W1971852037 @default.
- W2956113889 hasRelatedWork W2007442696 @default.
- W2956113889 hasRelatedWork W2030418865 @default.
- W2956113889 hasRelatedWork W2066496702 @default.
- W2956113889 hasRelatedWork W2136822078 @default.
- W2956113889 hasRelatedWork W2377520785 @default.
- W2956113889 hasRelatedWork W2589447549 @default.
- W2956113889 hasRelatedWork W2617991963 @default.
- W2956113889 hasRelatedWork W2891684308 @default.
- W2956113889 hasRelatedWork W2911250108 @default.
- W2956113889 hasRelatedWork W2970504229 @default.
- W2956113889 hasRelatedWork W2980685687 @default.
- W2956113889 hasRelatedWork W2989029453 @default.
- W2956113889 hasRelatedWork W3133176200 @default.
- W2956113889 hasRelatedWork W3146747392 @default.
- W2956113889 hasRelatedWork W3212287486 @default.
- W2956113889 hasRelatedWork W321613470 @default.
- W2956113889 hasRelatedWork W765180805 @default.
- W2956113889 hasRelatedWork W2131256589 @default.
- W2956113889 hasRelatedWork W2610614409 @default.
- W2956113889 isParatext "false" @default.
- W2956113889 isRetracted "false" @default.
- W2956113889 magId "2956113889" @default.
- W2956113889 workType "article" @default.